EMBT logo

Ember Therapeutics, Inc. (EMBT) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

EMBT representa a Ember Therapeutics, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 44/100

Ember Therapeutics, Inc. (EMBT) Resumen de Asistencia Médica y Tuberías

CEOJoseph Hernandez
Sede CentralNew York City, US
Año de la oferta pública inicial (OPI)2015
IndustriaBiotechnology

Ember Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing regenerative medicines based on bone morphogenetic protein-7 (BMP-7) technology. Their pipeline addresses osteoarthritis, chronic kidney disease, and metabolic diseases. The company holds a substantial patent portfolio related to BMP-7 and operates in the competitive biotechnology sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Ember Therapeutics operates in the regenerative medicine space with a focus on BMP-7 technology. Key value drivers include the advancement of their lead candidate, MT-006, through clinical trials for osteoarthritis, a large and growing market. Successful clinical trial outcomes and potential partnerships could drive significant value. The company's extensive patent portfolio provides a competitive advantage. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and the need for additional funding. With a market capitalization of $0.00B and a P/E ratio of -0.02, the company's valuation is highly dependent on the success of its clinical programs. The company's beta of -0.44 suggests lower volatility than the overall market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Ember Therapeutics focuses on bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines.
  • Lead product candidate MT-006 has completed Phase 2a clinical trial for osteoarthritis (OA).
  • The company holds approximately 450 patents covering BMP-7 and related technologies.
  • Ember Therapeutics targets diseases like chronic kidney disease (CKD), Alport's syndrome, obesity, and type 2 diabetes.
  • The company's market capitalization is $0.00B, reflecting its clinical-stage status.

Competidores y Pares

Fortalezas

  • Proprietary BMP-7 technology platform.
  • Extensive patent portfolio.
  • Clinical-stage product candidates.
  • Experienced management team.

Debilidades

  • Limited financial resources.
  • Dependence on clinical trial outcomes.
  • Lack of commercialized products.
  • OTC market listing.

Catalizadores

  • Upcoming: Publication of Phase 2a clinical trial results for MT-006 in osteoarthritis.
  • Upcoming: Initiation of Phase 2b clinical trials for MT-006.
  • Ongoing: Potential for strategic partnerships or collaborations with pharmaceutical companies.
  • Ongoing: Advancement of MT-007 and MT-009 through preclinical development.
  • Ongoing: Expansion of the BMP-7 patent portfolio.

Riesgos

  • Potential: Clinical trial failures for MT-006 or other product candidates.
  • Potential: Regulatory hurdles and delays in obtaining marketing approvals.
  • Potential: Competition from other biotechnology companies developing similar therapies.
  • Ongoing: Need for additional funding to support clinical development.
  • Ongoing: Risks associated with operating in the OTC market.

Oportunidades de crecimiento

  • Advancement of MT-006 for Osteoarthritis: Ember's lead candidate, MT-006, has completed Phase 2a clinical trials for osteoarthritis (OA). Osteoarthritis affects millions worldwide, representing a significant market opportunity. Successful completion of Phase 3 trials and subsequent regulatory approval could generate substantial revenue. The timeline for commercialization depends on clinical trial outcomes, but potential market entry could occur within the next 3-5 years.
  • Development of MT-007 for Chronic Kidney Disease and Alport Syndrome: MT-007 is in preclinical development for chronic kidney disease (CKD) and Alport syndrome, both of which represent significant unmet medical needs. The market for CKD therapies is substantial and growing. Successful preclinical and clinical development of MT-007 could lead to a valuable therapeutic option. The timeline for commercialization is longer, potentially 5-7 years, due to the early stage of development.
  • Expansion into Metabolic Diseases with MT-009: MT-009 is a preclinical candidate targeting metabolic diseases, including obesity and type 2 diabetes. These diseases are highly prevalent globally, creating a large market opportunity. Successful development of MT-009 could position Ember as a player in the metabolic disease space. The timeline for commercialization is estimated at 5-7 years, contingent on successful preclinical and clinical trials.
  • Leveraging the BMP-7 Patent Portfolio: Ember Therapeutics holds approximately 450 patents covering BMP-7 and related technologies. This extensive patent portfolio provides a competitive advantage and potential for licensing opportunities. Strategic partnerships and out-licensing of BMP-7 technology could generate revenue and expand the company's reach. The timeline for realizing value from the patent portfolio is ongoing, with potential for near-term and long-term opportunities.
  • Strategic Partnerships and Collaborations: Ember can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and distribution networks. Successful partnerships could significantly enhance Ember's prospects and expedite the delivery of its therapies to patients. The timeline for securing partnerships is ongoing, with potential for near-term and long-term agreements.

Oportunidades

  • Strategic partnerships with larger pharmaceutical companies.
  • Expansion into new therapeutic areas.
  • Out-licensing of BMP-7 technology.
  • Positive clinical trial results.

Amenazas

  • Clinical trial failures.
  • Regulatory hurdles.
  • Competition from other biotechnology companies.
  • Need for additional funding.

Ventajas competitivas

  • Extensive patent portfolio covering BMP-7 technology.
  • Clinical-stage product candidates targeting unmet medical needs.
  • Expertise in regenerative medicine and bone morphogenetic proteins.
  • Potential for strategic partnerships to accelerate development.

Acerca de EMBT

Ember Therapeutics, Inc., founded in 2010 and headquartered in New York City, is a clinical-stage biopharmaceutical company focused on developing regenerative medicines. The company's core technology revolves around the clinical application of bone morphogenetic protein-7 (BMP-7) to address significant unmet medical needs. Ember's primary focus is the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Their lead product candidates include MT-006, which has completed a Phase 2a clinical trial for osteoarthritis; MT-007, which has completed preclinical trials for CKD and Alport syndrome; MT-008, a preclinical trial completed candidate for Alport syndrome; and MT-009, a preclinical trial completed candidate for metabolic disease. Ember Therapeutics also possesses a significant intellectual property portfolio, holding approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. The company operates in the highly competitive biotechnology industry, seeking to advance its pipeline through clinical trials and potential partnerships.

Qué hacen

  • Develop regenerative medicines for osteoarthritis (OA).
  • Develop therapies for chronic kidney disease (CKD) and Alport's syndrome.
  • Research treatments for metabolic diseases like obesity and type 2 diabetes.
  • Focus on the clinical application of bone morphogenetic protein-7 (BMP-7).
  • Conduct preclinical and clinical trials to evaluate product candidates.
  • Hold a significant patent portfolio related to BMP-7 technology.
  • Seek strategic partnerships to advance development and commercialization.

Modelo de Negocio

  • Develop and patent regenerative medicine technologies.
  • Conduct preclinical and clinical trials to validate therapies.
  • Seek regulatory approval for product candidates.
  • Potentially commercialize therapies directly or through partnerships.

Contexto de la Industria

Ember Therapeutics operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The regenerative medicine market, in particular, is experiencing increasing demand due to the aging global population and the rising prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Ember's focus on BMP-7 technology differentiates it within this competitive environment. The company's success depends on navigating regulatory hurdles and securing funding for clinical trials.

Clientes Clave

  • Patients suffering from osteoarthritis (OA).
  • Patients with chronic kidney disease (CKD) and Alport's syndrome.
  • Individuals with metabolic diseases like obesity and type 2 diabetes.
  • Potential pharmaceutical partners seeking to license BMP-7 technology.
Confianza de la IA: 69% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Ember Therapeutics, Inc. (EMBT): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para EMBT.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para EMBT.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para EMBT.

MoonshotScore

44/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de EMBT en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Joseph Hernandez

CEO

Information on Joseph Hernandez's background is not available in the provided data. Therefore, a detailed biography cannot be provided. Further research would be required to gather information on his career history, education, previous roles, and credentials.

Historial: Information on Joseph Hernandez's track record is not available in the provided data. Therefore, a summary of his key achievements, strategic decisions, and company milestones under his leadership cannot be provided. Further research would be required to gather this information.

Información del mercado OTC de EMBT

The OTC Other tier represents the lowest tier of the OTC market, indicating that Ember Therapeutics may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with speculative ventures or those facing financial difficulties.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: As an OTC Other stock, EMBT's liquidity is likely limited. Trading volume may be low, and the bid-ask spread could be wide, making it difficult to buy or sell shares at desired prices. Investors may experience challenges in executing large trades without significantly impacting the stock price. Due diligence is crucial to assess trading patterns and potential price volatility.
Factores de riesgo OTC:
  • Limited financial disclosure.
  • Low trading volume and liquidity.
  • Potential for price manipulation.
  • Higher risk of fraud or mismanagement.
  • Limited regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the background and experience of the management team.
  • Assess the company's business plan and market opportunity.
  • Evaluate the company's competitive landscape.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Señales de legitimidad:
  • Existence of a valid business plan and market opportunity.
  • Experienced management team with relevant industry expertise.
  • Holding of patents related to BMP-7 technology.
  • Completion of Phase 2a clinical trial for MT-006.
  • Focus on addressing unmet medical needs.

Preguntas Comunes Sobre EMBT

¿Cuáles son los factores clave para evaluar EMBT?

Ember Therapeutics, Inc. (EMBT) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Proprietary BMP-7 technology platform.. Riesgo principal a monitorear: Potential: Clinical trial failures for MT-006 or other product candidates.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de EMBT?

EMBT actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de EMBT?

Los precios de EMBT se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre EMBT?

La cobertura de analistas para EMBT incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en EMBT?

Las categorías de riesgo para EMBT incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for MT-006 or other product candidates.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de EMBT?

La relación P/E para EMBT compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está EMBT sobrevalorada o infravalorada?

Determinar si Ember Therapeutics, Inc. (EMBT) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de EMBT?

Ember Therapeutics, Inc. (EMBT) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information on CEO background and track record is limited.
  • Disclosure status on OTC markets is unknown.
Fuentes de datos

Popular Stocks